NASDAQ:AGTCApplied Genetic Technologies Stock Price, Forecast & News

Applied Genetic Technologies' stock was trading at $3.84 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AGTC stock has increased by 25.0% and is now trading at $4.80. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Applied Genetic Technologies in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Applied Genetic Technologies.

Applied Genetic Technologies is scheduled to release its next quarterly earnings announcement on Thursday, September 24th 2020. View our earnings forecast for Applied Genetic Technologies.

Applied Genetic Technologies Corp (NASDAQ:AGTC) announced its quarterly earnings results on Wednesday, May, 13th. The biotechnology company reported ($0.50) EPS for the quarter, beating analysts' consensus estimates of ($0.55) by $0.05. View Applied Genetic Technologies' earnings history.

6 analysts have issued 1-year price targets for Applied Genetic Technologies' shares. Their forecasts range from $10.00 to $25.00. On average, they anticipate Applied Genetic Technologies' stock price to reach $16.50 in the next twelve months. This suggests a possible upside of 243.8% from the stock's current price. View analysts' price targets for Applied Genetic Technologies.

Media coverage about AGTC stock has trended very negative this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Applied Genetic Technologies earned a daily sentiment score of -3.5 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 9.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news aboutApplied Genetic Technologies.

Some companies that are related to Applied Genetic Technologies include Innate Pharma (IPHYF), Agenus (AGEN), Autolus Therapeutics (AUTL), Voyager Therapeutics (VYGR), PDL BioPharma (PDLI), Precision BioSciences (DTIL), Eiger Biopharmaceuticals (EIGR), Verona Pharma (TARA), CASI Pharmaceuticals (CASI), Cellular Biomedicine Group (CBMG), ADMA Biologics (ADMA), Tcr2 Therapeutics (TCRR), Gritstone Oncology (GRTS), Sutro Biopharma (STRO) and Pluristem Therapeutics (PSTI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Genetic Technologies investors own include Micron Technology (MU), SCYNEXIS (SCYX), Anavex Life Sciences (AVXL), Sorrento Therapeutics (SRNE), Agile Therapeutics (AGRX), Galmed Pharmaceuticals (GLMD), Crispr Therapeutics (CRSP), Allena Pharmaceuticals (ALNA), Fortress Biotech (FBIO) and Inovio Pharmaceuticals (INO).

Applied Genetic Technologies trades on the NASDAQ under the ticker symbol "AGTC."

Applied Genetic Technologies' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include DAFNA Capital Management LLC (6.37%), Sofinnova Investments Inc. (5.83%), Acadian Asset Management LLC (4.79%), Stonepine Capital Management LLC (3.22%), Ikarian Capital LLC (3.00%) and Portolan Capital Management LLC (2.61%). Company insiders that own Applied Genetic Technologies stock include Patrick Johan Hendrik Krol, Susan B Washer, William A Sullivan and William Aliski. View institutional ownership trends for Applied Genetic Technologies.

AGTC stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley. View insider buying and selling activity for Applied Genetic Technologies.

AGTC stock was purchased by a variety of institutional investors in the last quarter, including Sofinnova Investments Inc., DAFNA Capital Management LLC, Stonepine Capital Management LLC, Portolan Capital Management LLC, Ghost Tree Capital LLC, Ikarian Capital LLC, Russell Investments Group Ltd., and Assenagon Asset Management S.A.. Company insiders that have bought Applied Genetic Technologies stock in the last two years include Patrick Johan Hendrik Krol, Susan B Washer, William A Sullivan, and William Aliski. View insider buying and selling activity for Applied Genetic Technologies.

Shares of AGTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AGTC stock can currently be purchased for approximately $4.80.

Applied Genetic Technologies has a market capitalization of $123.65 million and generates $41.69 million in revenue each year. The biotechnology company earns $-2,010,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis. Applied Genetic Technologies employs 85 workers across the globe.

The official website for Applied Genetic Technologies is www.agtc.com.

Applied Genetic Technologies' mailing address is 14193 NW 119TH TERRACE SUITE 10, ALACHUA FL, 32615. The biotechnology company can be reached via phone at 386-462-2204.